What are the dosing recommendations, contraindications, major drug interactions, adverse effects, and alternative treatments for Paxlovid (nirmatrelvir + ritonavir) in patients with COVID‑19?

Paxlovid (Nirmatrelvir/Ritonavir) Clinical Issues

Paxlovid is highly effective for high-risk COVID-19 patients but requires meticulous drug interaction management due to ritonavir's potent CYP3A4 inhibition, which can cause life-threatening interactions with commonly prescribed medications. 1, 2

Indications and Timing

Consider nirmatrelvir/ritonavir for symptomatic patients with confirmed mild-to-moderate COVID-19 who are within 5 days of symptom onset and at high risk for progression to severe disease. 3 The medication must be initiated as soon as possible after diagnosis for maximum benefit. 1, 2

Paxlovid is not approved for pre-exposure or post-exposure prophylaxis. 1, 2

Standard Dosing

• 300 mg nirmatrelvir (two 150 mg tablets) + 100 mg ritonavir (one 100 mg tablet)
• Taken together twice daily for 5 days
• Administer at approximately the same time each day
• Can be taken with or without food 1, 2

Renal Dose Adjustments

Dosing must be adjusted based on eGFR 2:

Moderate renal impairment (eGFR 30-59 mL/min):

• 150 mg nirmatrelvir + 100 mg ritonavir twice daily for 5 days

Severe renal impairment (eGFR <30 mL/min), including hemodialysis:

• Day 1: 300 mg nirmatrelvir + 100 mg ritonavir once
• Days 2-5: 150 mg nirmatrelvir + 100 mg ritonavir once daily
• For hemodialysis patients: administer after dialysis on dialysis days 2, 4

Recent evidence demonstrates this regimen is well-tolerated and achieves adequate exposure in severe renal impairment. 4

Hepatic Considerations

Paxlovid is not recommended in severe hepatic impairment (Child-Pugh Class C). 1, 2 Ritonavir can cause hepatic transaminase elevations, clinical hepatitis, and jaundice. 1, 2

Absolute Contraindications

1, 2

1. History of clinically significant hypersensitivity to nirmatrelvir or ritonavir
2. Co-administration with drugs highly dependent on CYP3A for clearance where elevated concentrations cause serious/life-threatening reactions
3. Co-administration with potent CYP3A inducers (risk of treatment failure and resistance)

Critical Drug Interactions

The FDA includes a boxed warning specifically for drug interactions. Ritonavir is a potent CYP3A4 inhibitor that can lead to severe, life-threatening, or fatal events from drug accumulation. 1, 2, 5

High-Risk Medication Classes Requiring Management:

Statins (most common interaction, 28% of patients):

• Temporarily discontinue during 5-day treatment course 6, 7

Immunosuppressants (12% of patients):

• Tacrolimus: Discontinue or give microdose on day 1 only 8
• Cyclosporine: Reduce to 20% of initial dose 8
• mTOR inhibitors: Dose adjustment required 8
• Therapeutic drug monitoring essential 8

Direct oral anticoagulants (10.5% of patients):

• Apixaban: Common interaction requiring dose adjustment or temporary interruption 6, 7

Calcium channel blockers:

• Amlodipine: Affects 21.6% of patients, may require dose adjustment 6

Management Strategy:

Before prescribing, review ALL medications to assess potential interactions. 1, 2 Options include:

• Continue unchanged (77% of medications) 7
• Temporary interruption (14% of medications) 7
• Dose adjustment (6% of medications) 7
• Alternative therapy (3% of medications) 7
• Clinical or therapeutic drug monitoring 7

In long-term care facilities, 86% of residents had at least one potential drug interaction, with 60% having two or more. 6 This underscores the need for pharmacist consultation in complex cases.

Common Adverse Effects

The most common adverse reactions (≥1% incidence) are:

• Dysgeusia (altered taste)
• Diarrhea 1, 2

Less common but serious:

• Anaphylaxis
• Serious skin reactions (toxic epidermal necrolysis, Stevens-Johnson syndrome)
• Nausea and vomiting (particularly in dialysis patients) 9

Immediately discontinue Paxlovid if signs of clinically significant hypersensitivity or anaphylaxis occur. 1, 2

Special Populations

HIV-1 patients: Risk of developing HIV-1 protease inhibitor resistance in uncontrolled or undiagnosed HIV-1 infection. 1, 2

Hemodialysis patients: Case series demonstrate good tolerance and efficacy with appropriate dose adjustment, though nausea/vomiting may be more common. 9

Alternative Treatments

When Paxlovid is contraindicated or unsuitable due to drug interactions:

Molnupiravir is the recommended alternative antiviral for high-risk patients with mild-to-moderate COVID-19 within 5 days of symptom onset. 3, 10 It has fewer drug interactions but may be less effective than nirmatrelvir/ritonavir.

Not recommended:

• Ivermectin 3
• Sotrovimab 3

Clinical Pearls

• 86.7% of patients have at least one clinically relevant drug interaction 7
• Expert pharmacology consultation can identify options to navigate initial contraindications in 13.5% of cases 7
• The benefit of reducing hospitalization and death must be weighed against drug interaction risks for each individual patient 1, 2
• Nirmatrelvir exhibits absorption-limited nonlinear pharmacokinetics, reaching 11.7× the antiviral EC90 at peak and maintaining 5.4× EC90 at trough 11
• The 5-day treatment course is short, allowing for temporary medication interruptions in many cases 5